<DOC>
	<DOCNO>NCT00926614</DOCNO>
	<brief_summary>The aim study determine insulin sensitize thiazolidinedione plus lipid lowering agent ( statin ) improve sustained virologic response rate patient previously respond relapsed standard pegylated interferon ribavirin therapy .</brief_summary>
	<brief_title>Efficacy Actos Lipitor Pegasys &amp; Ribavirin CHC GT 1 Patients Who Relapsed Nonresponded Peg/Riba</brief_title>
	<detailed_description>The study evaluate use atorvastatin pioglitazone pre-treatment insulin resistance lipid level prior addition pegylated interferon ribavirin chronic hepatitis C ( CHC ) . If improvement see insulin resistance patient may position respond favorably current antiviral therapy consist pegylated interferon ribavirin . This study could demonstrate value pretreating continue treatment insulin resistance pioglitazone CHC , genotype 1 patient previously respond relapsed prior pegylated interferon ribavirin treatment . Changes lipids primary secondary endpoint study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>GT 1 previously treat pegylated interferon &amp; ribavirin &amp; either nonresponded relapse cessation therapy Insulin resistance Compensated liver disease WBC &lt; 3,000/ mm3 Neutrophil count &lt; 1,500/mm3 Platelets &lt; 65,000/ mm3 Albumin &gt; 3 gm/dL Participants metformin thiazolidinedione must 3month washout period Women pregnant breastfeeding Males pregnant partner Coinfection HAV , HBV , HIV Ophthalmic abnormality severe retinopathy Poorly control thyroid dysfunction Serum creatinine concentration &gt; 1.5 time ULN Severe psychiatric neuropsychiatric disorder History alcoholism drug addiction 1 year prior screening Seizure disorder control medication Significant cardiovascular dysfunction within past 12 month Chronic pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>GT1</keyword>
	<keyword>HCV</keyword>
	<keyword>non responder</keyword>
	<keyword>relapser</keyword>
</DOC>